Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Fund News: Edward Lampert, Bridgewater Associates, Trian Fund Management

This Hedge Fund Manager Bets He Can Dull Your Sweet Tooth (Bloomberg)
It started with a Nestlé Crunch bar. One night in 2012, Rob Goldstein returned from a New York kickboxing gym to his Upper East Side apartment and ate a healthy dinner. Then he saw the chocolate, which his son had left on the kitchen table. One bite quickly turned into eight. “I don’t know what came over me,” he says. He decided to find out. If he could reset his taste buds to how they were before that first bite, he thought, his willpower ought to stand a better chance. Since 1989, Goldstein has been a part of one of the most successful teams on Wall Street. He’s the right hand to Joel Greenblatt, whose hedge fund, Gotham Capital, posted annualized returns of more than 50 percent before returning money to clients in the mid-1990s.

Local Hedge Fund Manager Makes Peace With Canada (DealBreaker)
A year and a half ago, the Mounties launched a legal raid on Saba Capital, the New York hedge fund run by former Deutsche Bank wunderkind (it’s true; they used to have those, and even they lost the bank billions of dollars) Boaz Weinstein. In effect, the Mounties’ pension fund alleged that Weinstein had manipulated the price of a couple of bonds to screw Canada’s finest out of $12 million—and that’s 12 million American dollars, serious money north of the border. Ridiculous, right? Like we said, Weinstein doesn’t sweat over a $1.8 billion loss; he doesn’t even start paying attention until we’re dealing in nine figures.

With Ackman Out, Valeant Confronts Rocky Road to Revival (Bloomberg)
Turning around Valeant was never going to be easy. But the clock is ticking for Joe Papa, the chief executive of the struggling drug company. Even before Valeant Pharmaceuticals International Inc. lost its most vocal cheerleader last week, with the exit of hedge-fund mogul Bill Ackman, Wall Street analysts were virtually unanimous: The company’s old business model is broken. Growth, if there is any, will come slowly. And so Papa is running hard just to stand still. Since his arrival last year, following the departure of Valeant’s controversial architect, Mike Pearson, Papa has moved to stabilize Valeant’s shaky finances.

High-Flying Strategists At Big Banks Are Suddenly Playing Musical Chairs (CNBC)
Three months into the new year, some of Wall Street’s top firms have reshuffled their leading stock strategists. Jim Paulsen decided to retire from his role as chief investment strategist at Wells Capital Management, effective May 22, the company said Wednesday. Paulsen has been at Wells Fargo for 20 years. His departure follows similar moves in the industry. In mid-February, Adam Parker left his position as U.S. equity strategist at Morgan Stanley to become director of quantitative strategy at hedge fund Eminence Capital. Morgan Stanley named Mike Wilson, chief investment officer at Morgan Stanley Wealth Management, to take on the additional position of chief U.S. equity strategist in Parker’s place.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.